28.43USD+1.10%Mkt Cap: 819.01M USDP/E: —Last update: 2026-05-26
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small mole…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap819.01M USD
Enterprise Value440.78M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-25.20M USD
Revenue/Share—
Last Price28.43 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees35
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.23
PEG—
EV/EBITDA-9.85
EV/Revenue—
P/S—
P/B2.35
EPS (TTM)-1.36
EPS (Forward)-4.49
52W Range
13.3675% of range33.47
52W High33.47 USD
52W Low13.36 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-8.37%
ROA-8.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.21M USD
CapEx (TTM)52.00K USD
FCF Margin—
FCF Yield—
Net Debt-362.17M USD
Net Debt/EBITDA8.09
Balance Sheet
Debt/Equity0.01
Current Ratio35.67
Quick Ratio33.53
Book Value/Sh11.91 USD
Cash/Share12.75 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)45.00 USD
Target Range34.00 USD – 78.00 USD
# Analysts6
Ownership
Shares Out.28.68M
Float18.10M
Insiders0.27%
Institutions106.75%
Short Interest
Short Ratio12.7d
Short % Float15.94%
Short % Out.13.25%
Shares Short3.80M
Short (prev mo.)2.62M
Technical
SMA 5028.04 (+1.4%)
SMA 20021.77 (+30.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)210.58K
Avg Vol (10d)148.32K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—